While mutations in IDH1 have been shown to frequently occur with the 1p/19q co-deletion, mutations or LOH of TP53 have also been described in IDH1-mutant gliomas. Furthermore, TP53 alterations and the 1p/19q co-deletion are mutually exclusive events in glioma with IDH1 and 1p/19q found in oligodendroglial neoplasms while IDH1 and TP53 changes are concomitantly seen in astrocytomas. TP53 changes are reported in astrocytomas at a frequency of ~60% and are seen in over 90% of cases in which an individual is positive for an IDH1 change and negative for 1p/19q co-deletion. It should also be noted that TP53 mutations have been reported in IDH1-wild type (WT) lower-grade gliomas at a frequency of 14%. While TP53 is known to be frequently mutated and/or overexpressed in astrocytoma, there is little prognostic value from this finding in contrast to what is known in regards to IDH1-mutant /1p-19q co-deleted cases (Biomed Research International (2017): 8013575).